InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+10.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Bios Equity COF, LP, Director. Officer active across 1 company, notably Actuate Therapeutics, INC.. In total, 4 disclosures have been logged. Split: 2 buys · 1 sell. Total volume traded: €894k. Activity tracked since 14 August 2024. The latest transaction was filed on 27 June 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations4 total
71,428 shares@ US$7.000.68% mcap50.0% of flowCommon StockSEC:0001104659-25-063993:0
Ideal exit: 24 Mar 2026 (T+270)
71,428 shares@ US$7.0050.0% of flowCommon StockSEC:0001104659-25-063993
Ideal exit: 24 Mar 2026 (T+270)
5,314 shares@ US$8.004.3% of flowCommon StockSEC:0001104659-24-091372:0
884,427 sharesCommon StockSEC:0001104659-24-089825:0
4 of 4 declarations
About Bios Equity COF, LP
Bios Equity COF, LP is a Director at Actuate Therapeutics, Inc. As a board member, it contributes to the governance of the company and strategic decision-making. Its experience in the financial sector allows it to provide valuable insights.
